An additional 100,000 elective operations could be cancelled in England this winter as a result of the Omicron wave leading to increased hospital admissions.
A new clinical trial being led by the University of Birmingham and funded by the British Heart Foundation could help improve the recovery of children who undergo life-saving heart surgery.
Elderly care home residents who have previously contracted and survived COVID-19 develop much stronger and higher antibody and cellular immune responses to two doses of vaccination, research finds.
CARE Fertility has generously donated £202,800 to support the miscarriage research led by Professor Arri Coomarasamy and team at the University of Birmingham.
A UK-wide trial carried out in collaboration with the University of Birmingham show six COVID-19 vaccines are safe and boost immunity for people who have had two doses of Pfizer/BioNTech or Oxford/AstraZeneca.
The University of Birmingham and Huazhong University of Science and Technology (HUST) have signed a 'Key Partner' agreement that paves the way for a growth in their collaborations in both teaching and research.
LifeArc and PSC Support jointly award £898,774 for new research into primary sclerosing cholangitis (PSC), a rare disease where the body attacks its own liver, causing inflammation and scarring of the bile ducts.
Professor Willem van Schaik, Director of the Institute of Microbiology and Infection, writes an opinion piece on how the dynamics of infectious diseases will change on a warming planet.
University of Birmingham cancer experts have welcomed a £120,000 charity donation to purchase new equipment that will help to speed the development of new treatments which could save the lives of children and adults.
New research has found that the use of non-invasive breathing support to treat patients with moderate to severe COVID-19 in hospitals isn't linked to a heightened risk of transmitting infection to others.
So-called 'telemedicine' is less diagnostically accurate than in-person consultations and could increase health inequalities and barriers to accessing appropriate care.
New drug treatment regimen, using belimumab soon after rituximab, reduced a disease-related autoantibody and severe disease flares in lupus patients.